Clinical Trials

Clinical development is outmoded; we are witnessing serious attrition in cancer R&D. Perhaps it’s time to live and die by the mantra: “no biomarker, no trial”.

Despite clinical failures in the 1990s, pharma is (cautiously) ready to try again with oral peptide formulations.

Drug makers and regulators are taking steps towards transparency, but is it enough?

It is well established that the use of nanotechnology in medicine and more specifically drug delivery is spreading rapidly.

The techniques of laser diffraction and automated particle imaging support the fast, cost-effective development of nasal spray products, simultaneously providing the data required for regulatory compliance. This paper examines their application.

Taylor Dispersion measurements are used to monitor self-association and oligomeric state in a variety of buffer conditions.

Most pharma companies want to become more patient focused. But how? You could start by simply listening more carefully.

Dr Paul Kippax is looking at how recent innovations are substantially enhancing the value and informational productivity of some of our established and trusted analytical techniques.

Researchers examine the application and usefulness of nanoparticle tracking analysis and dynamic light scattering techniques in the characterization of liposomes used as drug delivery vehicles.

Progress is too often hampered by our inability to gather the information needed to make advances.